IVBH Presents Groundbreaking Data for Early Lung Cancer Detection at the ASCO® 2023 Annual Meeting

Eric Kristiansen • Jun 04, 2023

IVBH's novel RNA approach to early detection demonstrates strong sensitivity and specificity for early lung cancer detection, in a large, predominantly early-stage, independent validation cohort

NEWPORT BEACH, Calif., June 2, 2023 /PRNewswire/ -- IVBH, a leader in liquid biopsy technology, specializing in noninvasive early detection, will unveil groundbreaking data from an independent validation study of the company's proprietary LiquidLung lung cancer detection technology, at the ASCO® 2023 Annual Meeting. This study of 3,744 subjects, including patients with pre-operative lung cancer and non-cancer controls, demonstrated accurate detection of early-stage lung cancer across prevalent histologic types and subgroups of patients with lung cancer, including never-smokers.


"Traditionally, the liquid biopsy field has focused on detecting cancer cells shed into the bloodstream by a tumor," said Marty Keiser, IVBH Founder-CEO. "IVBH is revolutionizing this approach, not by sequencing cancer cells, rather by harnessing the dynamic response of the patient — through changes in RNA gene expression — enabling more sensitive and specific disease detection in the earliest stages of disease."

In the poster, the LiquidLung RNA-model, which used machine learning, detected lung cancer with 98% sensitivity, 89% specificity in the held-out test set of the independent validation cohort. Incorporating age and gender brought balance to the overall accuracy of the technology, achieving 95.5% sensitivity, 90.3% specificity in the held-out test set.


This peer-reviewed research represents a significant step forward in the early detection of lung cancer. 


"This peer-reviewed research represents a significant step forward in the early detection of lung cancer," said Dr. Brendon Stiles, Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein. "It moves us away from tumor-only approaches, which have limited sensitivity or specificity. The machine learning approach, combined with blood-based RNA gene expression profiles, and available demographics and clinical data, is immediately scalable and holds tremendous potential for guiding clinically actionable decisions across the entire lung cancer care continuum, and a promising new direction for early detection for a wide variety of diseases."


Abstract 8557/Poster Bd #184: Development of a novel blood-based RNA gene expression platform for early-stage lung cancer diagnosis

Authors: Keiser M, et al.

Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Date/Time: June 4, 2023, 8 – 11am CT

Location: Hall A


About IVBH:


Since its founding in 2018, IVBH has pioneered a new frontier in early detection — harnessing the dynamic genomic response of the patient, through changes in RNA gene expression, to detect disease in the earliest stages. IVBH has conceived, created and developed an extensive pipeline of industry-first clinical assays, addressing major unmet needs in breast, lung and metabolic health. Visit ivbh.studio and follow the company on LinkedIn.


Contact: info@ivbh.studio


SOURCE IVBH

02 Dec, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
02 Dec, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
16 Nov, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
Show More
02 Dec, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
02 Dec, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
16 Nov, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
By Marty Keiser 22 Mar, 2023
A decade in the making, AI is suddenly everything, everywhere, all at once. In this article I outline three major themes emerging in the current environment. 1. Industrialization. We have officially entered the industrialization era of AI. With the most complex technical foundation already having been laid, success is no longer about the quality of your code, but rather the quality of your prompts. Any person with the right idea, the right focus, and the right prompts, can now solve any problem, in any industry, regardless of their background, socioeconomic status or geography. The floodgates for innovation have officially been opened. 2. Business disruption. Big missions no longer require big teams, big infrastructure, or big budgets. In fact, in the age of abundance, these things are detractors from the mission. Regime change is underway and small, nimble, multi-disciplinary teams who leverage big data and generalized AI tools in a highly specialized way should not be underestimated or undervalued. Size is no longer an advantage, it’s an Achilles heel. 3. People disruption. AI has reached a point where it can now scale humans. The net effect of this is a devaluing of humans without AI, and a devaluing of AI without humans. The two can no longer be treated as mutually exclusive. Humans who fully embrace AI with intention and purpose will win, and they will win big. (The humans who do this most effectively within this decade will be the winners for the next century.)
By Eric Kristiansen 17 Mar, 2023
"Marty Keiser, an accomplished entrepreneur and finance professional, shares his wealth of knowledge and experience in growing and scaling a successful business. From navigating the transition into the science industry (from the finance world), key lessons learned in building a strong and effective team, the challenges faced during growth, and the importance of preserving company culture, Marty sheds light on topics that any entrepreneur or leader can benefit from. He also offers practical insights on defining core values, using those values to guide the hiring process, and identifying the right individuals for your teams. All valuable information for those seeking to grow their own business or improve their leadership within their organization. Marty is also sharing practical resources for listeners!"
By Eric Kristiansen 10 Jan, 2023
R.E.D. campaign to solidify IVBH's leadership position within noninvasive early detection after achieving >90% sensitivity in stage I disease detection in expanded data across 5,000+ case-control subjects
By Eric Kristiansen 10 Jan, 2023
Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm
By Eric Kristiansen 23 Nov, 2022
Experts say lung cancer screening is an important and easy diagnostic test. Weedezign/Getty Images
By Eric Kristiansen 28 Jun, 2022
This multi-year partnership solidifies IV BioHoldings as an AI-powered organization and will further accelerate the company’s clinical and commercial efforts to transform the paradigm of precision health by detecting, diagnosing and treating patients as individuals, at scale.
By Eric Kristiansen 17 Jun, 2022
Marty Keiser is the Walt Disney of BioTech. Marty is an imagineer at heart who is seeking to conceive, create and scale the detection, diagnosis and treatment of disease. At the core of everything Marty does is his love for people and his passion to save lives. Listen in to learn more about Marty’s unique to developing solutions that break the norms of how biotech is done and his unique mindset to building a team of fellow imagineers to impact over a billion lives. Some highlights of our conversation include: 1:32 – Who is Marty Keiser and what IV BioHoldings (IVBH) is up to? 5:09 – The Motivation Behind Everything 13:26 – Courage is required, not confidence 15:52 – Creating in the “negative space” 27:04 – Building a space to create and challenge norms 30:25 – A servant instead of a savior mindset in biotech 35:25 – A path to a servant approach 37:28 – The next billionaires will have impacted a billion lives 39:47 – Advice to my pre-CEO self To learn more about Marty, follow him on LinkedIn: linkedin.com/in/marty-keiser-29181b4/ To learn more about IVBH: https://www.ivbh.studio/
More Posts
Share by: